Basic Research
- Taxonomy
- Animal models
- Immunology
- Regulation of gene expression
- Transformation and carcinogenesis
- Structural biology
- Virus - host interactions
- Virus life cycle
- Genomics of HPV-associated disease
- Papillomavirus vaccines (i.e. new developments)
- Other basic research
Clinical Research
- HPV diagnostics and biomarkers I: HPV triage technologies
- HPV diagnostics and biomarkers II: Validation platforms (e.g. Valgent)
- HPV diagnostics and biomarkers III: Quality and performance verification for clinical HPV tests
- HPV self-collection
- Diagnosis and management of cervical cancer and its precursors
- Diagnosis and management of anal cancer and its precursors
- Diagnosis and management of penile, vulvar and vaginal cancer and precursors
- Diagnosis and management of oropharyngeal, head and neck cancer
- Diagnosis and management of genital and skin warts
- Diagnosis and management of HPV associated skin lesions other than warts
- Prophylactic vaccines – clinical aspects
- Therapeutic vaccines – clinical aspects
- Management of HPV disease in HIV-infected people
- Treatment of precancer in low resource settings
- Cochrane reviews of HPV vaccination and screening
- Treatment of HPV-related disease
- Recurrent Respiratory Papillomatosis
- Other clinical research
Public Health / Epidemiology
- Global impact of HPV and cervical cancer prevention
- Epidemiology: natural history/global burden/risk factors
- Screening for HPV related disease: implementation, evaluation and impact
- Vaccine safety: new evidence and public perception
- Quality standards and methods for economics and mathematical modelling (e.g. HPV-FRAME)
- Cancer control in Indigenous peoples.
- Cancer control in Culturally And Linguistically Diverse Groups (CALD).
High resource settings
37. Screening for HPV related disease: implementation, evaluation and impact38. Vaccination: implementation, evaluation and impact39. Economics and mathematical modelling in HIC 40. Primary HPV vs co-testing with HPV and cytology
Low and middle income (LMIC) settings
41. Screening for HPV related disease screening: implementation, evaluation and impact'42. Scale up of HPV vaccination in Gavi-eligible countries43. Cervical screening and combined screening vaccination strategies in LMIC44. Economics and mathematical modelling for LMIC 45. Vaccine and screening implementation in non GAVI-eligible/middle income countries 46. Psychosocial impact of new HPV and cervical cancer prevention strategies 47. Other public health / epidemiology research